Терапия рефрактерных и рецидивирующих Т-лимфобластных лимфом из клеток-предшественниц у детей и подростков: современное состояние проблемы и перспективы дальнейших исследований

Введение. Несмотря на достигнутые успехи в терапии лимфобластных лимфом из клеток-предшественниц (ЛБЛ), важной задачей остается улучшение показателей выживаемости в группе больных Т-клеточными лимфобластными лимфомами (Т-ЛБЛ). Группу особого неблагоприятного прогноза составляют больные с рецидивами и рефрактерными формами (Р/Р) Т-ЛБЛ.

Цель  — обзор литературы, посвященной использованию таргетных и  иммунных препаратов, а  также клеточных и трансплантационных методов в лечении Р/Р Т-ЛБЛ.

Основные сведения. Современная клиническая онкогематология располагает широким арсеналом методов для лечения Р/Р Т-ЛБЛ, включающих интенсивные химиотерапевтические схемы, таргетные, трансплантационные технологии и терапию Т-лимфоцитами с химерным антигенным рецептором, но даже их сочетание в настоящее время не позволяет добиться оптимистичных результатов в данной прогностически неблагоприятной группе больных. Возможно, создание таргетных препаратов, направленных на сигнальные пути с участием NOTCH, PI3K/AKТ/mTOR, JAK/STAT и  MAPK, в  сочетании с  имеющимися терапевтическими возможностями позволит улучшить показатели выживаемости больных.

1. Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul; 36(7): 1720–48. DOI: 10.1038/s41375-022-01620-2.

2. Oschlies I., Burkhardt B., Chassagne-Clement С., et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011; 35(6): 836–44. DOI: 10.1097/PAS.0b013e318213e90e.

3. Béné M.C., Nebe T., Bettelheim P., et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011; 25(4): 567–74. DOI: 10.1038/leu.2010.312.

4. Béné M.C., Castoldi G., Knapp W., et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995; 9(10): 1783–6.

5. Dworzak M.N., Buldini B., Gaipa G., et al. International-BFM-FLOW-network. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018; 94(1): 82–93. DOI: 10.1002/cyto.b.21518.

6. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937–51. DOI: 10.1182/blood-2009-03-209262.

7. Temple W.C., Mueller S., Hermiston M.L., et al. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults. Best Pract Res Clin Haematol. 2023; 36(1): 101449. DOI: 10.1016/j.beha.2023.101449.

8. Lones, M.A., Heerema, N.A., Le Beau, et al. (2007) Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genetics and Cytogenetics. 172: 1–11.

9. Basso K., Mussolin L., Lettieri A., et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes and Cancer. 2011; 50: 1063–75.

10. Feng H., Stachura D.L., White R.M., at el. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell. 2010; 18(4): 353–66. DOI: 10.1016/j.ccr.2010.09.009.

11. Callens C., Baleydier F., Lengline E., et al. Clinical impact of NOTCH1 and/ or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol. 2012; 30(16): 1966–73. DOI: 10.1200/JCO.2011.39.7661.

12. Ben A.R., Asnafi V., Leguay T., et al. Group for Research on Adult Acute Lymphoblastic Leukemia. Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/ BAALC expression: a GRAALL study. Blood. 2011; 118(19): 5099–107. DOI: 10.1182/blood-2011-02-334219.

13. Burkhardt B., Bruch J., Zimmermann M., et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006; 20(8): 1422–9. DOI: 10.1038/sj.leu.2404275.

14. Burkhardt B., Moericke A., Klapper W., et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma. 2008; 49(3): 451–61. DOI: 10.1080/10428190701824551.

15. Veltri G., Lovisa F., Cortese G., et al. Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia. Front Oncol. 2022; 12: 913487. DOI: 10.3389/fonc.2022.913487.

16. Burkhardt B., Hermiston M.L. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019; 185(6): 1158–70. DOI: 10.1111/bjh.15793.

17. Алешина О.А., Гальцева И.В., Котова Е.С. и др. Результаты терапии острых Т-лимфобластных лейкозов/лимфом: данные многоцентрового проспективного рандомизированного исследования ОЛЛ -2016. Онкогематология. 2023; 18(1): 20–30. DOI: 10.17650/1818-8346-2023-18-1-20-30.

18. Schmidt E., Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol. 2013; 30(6): 484–508. DOI: 10.3109/08880018.2013.789574.

19. Cohen M.H., Johnson J.R., Justice R., et al. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008; 13(6): 709–14. DOI: 10.1634/theoncologist.2006-0017.

20. Гаврилина О.А., Котова Е.С., Паровичникова Е.Н. и др. Применение неларабина у взрослых больных с рефрактерным течением / рецидивом острого Т-лимфобластного лейкоза / лимфомы: опыт одного центра. Гематология и трансфузиология. 2019; 64(4): 382–95. DOI: 10.35754/0234-5730-2019-64-4-382-395.

21. Candoni A., Lazzarotto D., Ferrara F., et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/ refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. Am J Hematol. 2020; 95(12): 1466–72. DOI: 10.1002/ajh.25957.

22. Delgado-Martin C., Meyer L.K., Huang B.J., et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017; 31(12): 2568–76. DOI: 10.1038/leu.2017.136.

23. Hui Shi, Kai Hu. Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/Lymphoma Patients: SingleArm, Open-Label, Phase I Study. Blood. 2022; 140(Suppl. 1): 9480–1. DOI: 10.1182/blood-2022-165210.

24. Polgárová K., Otáhal P., Šálek C., et al. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies. Front Oncol. 2022; 12: 876758. DOI: 10.3389/fonc.2022.876758.

25. De Smedt R., Peirs S., Morscio J., et al. Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica. 2019; 104(1): e17–20. DOI: 10.3324/haematol.2018.199257.

26. Angiolillo A.L., Yu A.L., Reaman G., et al. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children’s Oncology Group report. Pediatr Blood Cancer. 2009; 53(6): 978–83. DOI: 10.1002/pbc.22209.

27. Zheng W., Medeiros L.J., Young K.H., et al. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014; 55(3): 624–7. DOI: 10.3109/10428194.2013.820293.

28. DiNardo C.D., Lachowiez C.A., Takahashi K., et al. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021; 39(25): 2768–78. DOI: 10.1200/JCO.20.03736.

29. Gibson A., Trabal A., McCall D., et al. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel). 2021; 14(1): 150. DOI: 10.3390/cancers14010150.

30. Pullarkat V.A., Lacayo N.J., Jabbour E., et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021; 11(6): 1440–53. DOI: 10.1158/2159-8290.CD-20-1465.

31. Rahmat L.T., Nguyen A., Abdulhaq H., et al. Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant. Case Rep. Hematol. 2018; 2018: 6092646. DOI: 10.1155/2018/6092646.

32. Farhadfar N., Li Y., May W.S., et al. Venetoclax and Decitabine for Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia: A Case Report and Review of Literature. Hematol. Oncol. Stem Cell Ther. 2021; 14: 246–51. DOI: 10.1016/j.hemonc.2019.10.002.

33. Zappone E., Cencini E., Defi na M., et al. Venetoclax in Association with Decitabine as Effective Bridge to Transplant in a Case of Relapsed Early T-Cell Lymphoblastic Leukemia. Clin. Case Rep. 2020; 8: 2000–2. DOI: 10.1002/ccr3.3041.

34. Rosolen A., Perkins S.L., Pinkerton C.R., et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015; 33(18): 2112–8. DOI: 10.1200/JCO.2014.59.7203.

35. Campana D. Monitoring minimal residual disease in pediatric hematologic malignancies. Clin Adv Hematol Oncol. 2007; 5(11): 876–7, 915.

36. Stark, B., Avigad, S., Luria, D., et al. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer. 2009; 52(1): 20–5. DOI: 10.1002/pbc.21823.

37. Hayashi R.J., Hermiston M.L., Teachey D., et al. MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children’s Oncology Group Trial AALL1231. Blood. 2024. DOI: 10.1182/blood.2023021184.

38. Lovisa F., Gallingani I., Varotto E., et al. Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience. Diagnostics. 2021; 11(9): 1594. DOI: 10.3390/diagnostics11091594.

39. Burkhardt B.,Taj M., Garnier N., et al. Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. Cancers. 2021; 13(9): 2075. DOI: 10.3390/cancers13092075.

40. Burkhardt B., Reiter A., Landmann E., et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol. 2009; 27(20): 3363–9. DOI: 10.1200/JCO.2008.19.3367.

41. Gross T.G., Hale G.A., He W., et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010; 16(2): 223–30. DOI: 10.1016/j.bbmt.2009.09.021.

42. Mitsui T., Mori T., Fujita N., et al. Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer. 2009; 52(5): 591–5. DOI: 10.1002/pbc.21941.

43. Michaux K., Bergeron C., Gandemer V., et al. SFCE and the EORTC children leukemia group. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols. Pediatr Blood Cancer. 2016; 63(7): 1214–21. DOI: 10.1002/pbc.25990.

44. Jacoby E., Shahani S.A., Shah N.N. Updates on CAR T-cell therapy in B-cell malignancies. Immunol Rev. 2019; 290(1): 39–59. DOI: 10.1111/imr.12774.

45. Raje N., Berdeja J., Lin Y., et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019; 380(18): 1726– 37. DOI: 10.1056/NEJMoa1817226.

46. Sánchez-Martínez D., Baroni M.L., Gutierrez-Agüera F., et al. Fratricideresistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019; 133(21): 2291–304. DOI: 10.1182/blood-2018-10-882944.

47. Tong C., Zhang Y., Liu Y., et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020; 136(14): 1632–44. DOI: 10.1182/blood.2020005278.

48. Mamonkin M., Rouce R.H., Tashiro H., et al. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015; 126(8): 983–92. DOI: 10.1182/blood-2015-02-629527.

49. Maciocia P.M., Wawrzyniecka P.A., Philip B., et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017; 23(12): 1416–23. DOI: 10.1038/nm.4444.

50. Cooper M.L., Choi J., Staser K., et al. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018; 32(9): 1970–83. DOI: 10.1038/s41375-018-0065-5.

51. Tang J., Li J., Zhu X., et al. Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget. 2016; 7(23): 34070–83. DOI: 10.18632/oncotarget.8710.

52. Yu Y., Li J., Zhu X., et al. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomedicine. 2017; 12: 1969–83. DOI: 10.2147/IJN.S127575.

53. Zhang M., Chen D., Fu X., et al. Autologous Nanobody-Derived FratricideResistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory Tcell Acute Lymphoblastic Leukemia/Lymphoma. Clin Cancer Res. 2022; 28(13): 2830–843. DOI: 10.1158/1078-0432.CCR-21-4097.

54. Maciocia P.M., Wawrzyniecka P.A., Philip B., et al. Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017; 23(12): 1416–23. DOI: 10.1038/nm.4444.

55. Feng J., Xu H., Cinquina A., et al. Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells. Stem Cell Rev Rep. 2021; 17(2): 652–61. DOI: 10.1007/s12015-020-10092-9.

56. Xie L., Ma L., Liu S., et al. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. Int Immunopharmacol. 2021; 96: 107731. DOI: 10.1016/j.intimp.2021.107731.

57. Reinhold U., Abken H., Kukel S., et al. CD7- T cells represent a subset of normal human blood lymphocytes. J Immunol. 1993; 150(5): 2081–9.

58. Lu P., Liu Y., Yang J., et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood. 2022; 140(4): 321–34. DOI: 10.1182/blood.2021014498.